arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

IDEXX LABORATORIES INC /DE

IDXX
$706.67 ▲ +30.77 (+4.55%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

IDEXX LABORATORIES INC /DE shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $56.8B
Dividend Yield —
Revenue Growth 10.4% ↗
Op. Margin 31.6% ↗
ROIC 52.9% ↗
FCF / Share $13.14 ↗
Trailing P/E 53.7x
Price / Book 35.1x
FCF Yield 1.9%
Debt / Equity 0.28
info Valuation on last close. End-of-day price, Nov 9, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.30B
↑ +10.4% —
Net Income Profit after all expenses
$1.06B
↑ +19.3% —
Operating Margin Operating profit as % of sales
31.6%
↑ +9.2% 88th
FCF / Share Free cash flow per share
$13.14
↑ +34.1% —
Long-Term Debt Long-term obligations
$450.00M
↓ -27.2% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
87
Returns ↓
98
Financial Health →
79
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 19 years · 73 quarters